| Title： | Chinese expert consensus recommendations for management of Hepatitis B and C Virus reactivation in Chinese female patients with breast cancer during chemotherapy |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinicians specializing in breast diseases in China |
| Evidence classification method： | The evidence grading system was developed by incorporating elements of the GRADE system along with insights gleaned from clinical studies conducted in China and expert clinical experience. |
| Development unit： | the Society of Breast Cancer Integration and Rehabilitation of China Anti-Cancer Association, Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Surgery Expert Working Group of the Surgeons' Branch of the Chinese Medical Doctor Association, the Society of Clinical Cancer Research Administration of China Anti-Cancer Association, Chongqing Federation of Clinical Medical Research, the Society of Onco-endocrinology of Chongqing Anti-Cancer Association |
| Registration time: | 2024-06-12 |
| Registration number： | PREPARE-2024CN793 |
| Purpose of the guideline: | Hepatitis B virus (HBV) infection is a pervasive global health challenge, with China classified as a region of moderate to high endemicity for HBV. Concurrently, the prevalence of hepatitis C virus (HCV) infection warrants significant attention. Chemotherapy is a common therapeutic modality for breast cancer patients; however, individuals with chronic hepatitis viral infections are at an elevated risk of viral reactivation during chemotherapy. Reactivation of HBV and HCV can lead to a significant rise in serum aminotransferase levels and may precipitate severe complications such as fulminant hepatitis and acute hepatic failure. These complications can result in the discontinuation of chemotherapy and, in the most severe cases, patient mortality, thereby adversely impacting the oncological treatment process and prognosis. Appreciating the complexities of HBV and HCV reactivation during chemotherapy for breast cancer is crucial for the development of standardized prophylactic and therapeutic interventions aimed at enhancing patient quality of life and improving clinical outcomes. In light of this, a panel of experts, drawing upon the latest literature and clinical insights from multiple centers, has engaged in focused deliberations and authored the " Chinese expert consensus recommendations for management of Hepatitis B and C Virus reactivation in Chinese female patients with breast cancer during chemotherapy" This consensus document is intended to serve as a reference for the standardized management of HBV and HCV reactivation in this patient population, with the goal of augmenting the quality of life and clinical prognosis for breast cancer patients. |
Latest registration
